Reportlinker Adds The Top 10 Pharmaceutical Companies in Latin America: Growth Performance, Strategies and SWOT Analysis

NEW YORK, May 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Top 10 Pharmaceutical Companies in Latin America: Growth performance, strategies and SWOT analysis

http://www.reportlinker.com/p0201022/The-Top-10-Pharmaceutical-Companies-in-Latin-America-Growth-performance-strategies-and-SWOT-analysis.html

The leading pharmaceutical companies in Latin America comprise multinational companies and domestic players. Brazil, Mexico, Venezuela and Argentina remained the major markets in Latin America with a market share of around 90%. This report provides an insight into the current state of the Latin American pharmaceutical industry, market structure, pricing, regulation, as well as evolving trends. This report profiles the top ten pharmaceutical companies in Latin America and provides a brief summary of the 11 to 20 players. The report also gives a strategic insight into the companies , brands, therapeutic classes and geographic breakdown of the revenue generated by these companies in Latin America. The top 10 companies were assessed on following parameters: each company's market share in the Latin American pharmaceutical market; key marketed products, geographic and therapeutic focus; growth strategies; key mergers and acquisitions; business-related strengths and weaknesses of these companies; and insights into the opportunities and threats facing them.

Key features of this report

• Market dynamics of the Latin American pharmaceutical market during the period 2004–08.
• Key market drivers and resistors in the Latin American market.
• Trends of the Latin American pharmaceutical market.
• Profile of top 10 players in the Latin American pharmaceutical market.
• Company analysis and market share of the top 10 players in the Latin American pharmaceutical market.

Scope of this report

• Develop insights for the Latin American pharmaceutical market, pricing and regulation, intellectual property rights and trends in these countries.
• Quickly understand how recent events are affecting the performance of major company's products and how their marketers are confronting competitive challenges in the Latin American market.
• Gain up-to-date competitive intelligence across a wide-range of marketed products, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Latin American pharmaceutical market.
• Save time, money and resources on analyzing the performance of the key Latin American pharmaceutical companies using this report.

Key Market Issues

• Regulatory environment in Latin America: The regulatory frameworks in Latin American countries have improved rapidly after they became signatories to TRIPS and various other international trade treaties. Overall, the aim of regional regulatory protocols to reduce pharmaceutical costs have indirectly promoted the generic industry.
• Rising trial registrations: Global drug giants have all entered Latin America for conducting clinical trials in recent years. An increase in research investments is result of the fast-paced regional socioeconomic transformation. Apart from the rising economic status, which has ensured better return on investments, improvement in healthcare infrastructure played an important role in attracting clinical trial projects from multinational pharmaceutical companies to the region.
• Regulatory harmonization and tie-ups: In the last few years, there has been increased activity in regulatory interaction between the Latin American countries. These countries are also involved in collaborations with regulators of EU nations. The intention is to harmonize the regulatory framework in the region.
• Compulsory licensing trends in Latin America: The compulsory licensing policy of Latin American countries is modeled on those used in most developed countries. Such an action is taken only when certain life sustaining drugs are in short supply.

Key findings from this report

• Latin American economies have been relatively less affected by the global economic meltdown compared to their developed counterparts.
• In 2008 the top 10 companies managed to capture around 40% of the Latin American market. Brazil followed by Mexico remained the leading markets in the Latin American region.
• The regulatory scenario in the Latin American region is continuously evolving, despite the fact that improvements in patent legislation protection of intellectual property are uncertain.
• According to Pharmaceutical Research and Manufacturers of America (PhRMA, US), lack of implementation of data exclusivities, non-approval of second use patent, drug counterfeiting and the regulatory backlogs are the major concerns in Latin American market.

Key questions answered

• What was the market size of the Latin American pharmaceutical market in 2008?
• What are the important trends in the Latin American market?
• Who were the top 10 players in the Latin American market in 2008?
• How are the companies positioned in the Latin American market in terms of geographic focus?
• Which are the key therapeutic areas in Brazil, Mexico, Venezuela, Argentina, Colombia, Chile & Peru?

List of Tables

The Top 10 Pharmaceutical Companies in Latin America

Executive summary 14

Industry overview 14

Sanofi-Aventis 15

Novartis 16

Bayer 17

Pfizer 18

Schering Plough 19

EMS 20

GlaxoSmithKline (GSK) 21

Boehringer Ingelheim 22

Roche 23

J&J (Johnson & Johnson) 24

Chapter 1 Introduction 26

What is this report about? 26

Methodology 26

Chapter 2 Industry overview 30

Summary 30

Introduction 31

Latin American market: size and growth 31

Key market drivers and resistors 33

Market drivers 33

Market resistors 34

Competitive landscape 35

Competitive position of the top 10 companies 35

Comparative analysis of the top 10 companies 37

Trends in the Latin American market 39

Regulatory environment in Latin America 39

Intellectual property 39

Brazil 39

Mexico 40

Venezuela 40

Argentina 41

Rising trial registrations 41

Regulatory harmonization and collaborations 41

Compulsory licensing trends in Latin America 41

Generic drug policy 42

Prescription policies 43

Chapter 3 Sanofi-Aventis 46

Summary 46

Introduction 47

Geographic focus 47

Marketed products 49

Therapeutic focus 49

Research and development 50

Growth strategies 51

Strengthening presence in Latin America 52

Growing business in the vaccine sector 52

SWOT analysis 53

Chapter 4 Novartis 56

Summary 56

Introduction 57

Geographic focus 57

Marketed products 59

Therapeutic focus 59

Research and development 60

Growth strategies 61

Sandoz, second largest generic player globally 61

Glivec/Gleevec positioned as flagship Novartis brand 62

Breadth of prescription pharma portfolio to provide insulation against generic threats 62

Diversification, the corporate mantra at Novartis 63

SWOT analysis 63

Chapter 5 Bayer 66

Summary 66

Introduction 67

Geographic focus 67

Marketed products 69

Therapeutic focus 69

Research and development 71

Growth strategies 71

Focus in healthcare for long-term profitability 71

New products, key for success in Latin America 72

SWOT analysis 73

Chapter 6 Pfizer 76

Summary 76

Introduction 77

Geographic focus 77

Marketed products 78

Therapeutic focus 79

Research and development 80

Growth strategies 81

M&A activities to drive sales 81

Broader therapy focus 82

SWOT analysis 83

Chapter 7 Schering Plough 86

Summary 86

Introduction 87

Geographic focus 87

Marketed products 88

Therapeutic focus 89

Research and development 90

Growth strategies 91

M&A activities to increase the companies revenue generation 91

Building a more diverse prescription drug offering to protect revenues 92

SWOT analysis 93

Chapter 8 EMS 96

Summary 96

Introduction 97

Geographic focus 97

Marketed products 98

Therapeutic focus 98

Research and development 99

Growth strategies 99

SWOT analysis 100

Chapter 9 GSK (GlaxoSmithKline) 102

Summary 102

Introduction 103

Geographic focus 103

Marketed products 104

Therapeutic focus 105

Research and development 106

Growth strategies 107

Growing diversified global business 108

Development of vaccine business 108

Continued investment in biologics 109

Delivering more products of value to the market 109

Simplify the operating model to support a diverse and growing business 110

SWOT analysis 111

Chapter 10 Boehringer Ingelheim 114

Summary 114

Introduction 115

Geographic focus 115

Marketed products 116

Therapeutic focus 117

Research and development 118

Growth strategies 119

Broader therapeutic coverage to open a greater range of opportunities 119

SWOT analysis 120

Chapter 11 Roche 122

Summary 122

Introduction 123

Geographic focus 123

Marketed products 124

Therapeutic focus 125

Research and development 126

Growth strategies 127

SWOT analysis 128

Chapter 12 J&J (Johnson & Johnson) 130

Summary 130

Introduction 130

Geographic focus 131

Marketed products 132

Therapeutic focus 132

Research and development 133

Growth strategies 134

Increasing threat of generic exposure Error! Bookmark not defined.

Lifecycle management to retain patients 134

SWOT analysis 135

Chapter 13 Other major players 138

AstraZeneca 138

Introduction 138

Geographic focus 138

Marketed products 140

Therapeutic focus 140

Research and development 142

Ache Labs 142

Introduction 142

Geographic focus 143

Marketed products 143

Therapeutic focus 144

Research and development 145

Medley 146

Introduction 146

Geographic focus 147

Marketed products 148

Therapeutic focus 148

Research and development 149

Merck & Co. 150

Introduction 150

Geographic focus 150

Marketed products 152

Therapeutic focus 152

Research and development 154

Merck KGaA 154

Introduction 154

Geographic focus 155

Marketed products 156

Therapeutic focus 156

Research and development 157

Nycomed Pharma 158

Introduction 158

Geographic focus 159

Marketed products 160

Therapeutic focus 161

Research and development 162

Eli Lilly 162

Introduction 162

Geographic focus 163

Marketed products 164

Therapeutic focus 164

Research and development 165

Wyeth 166

Introduction 166

Geographic focus 167

Marketed products 167

Therapeutic focus 168

Research and development 169

Eurofarma 170

Introduction 170

Geographic focus 170

Marketed products 172

Therapeutic focus 172

Research and development 173

Teva 174

Introduction 174

Geographic focus 175

Marketed products 176

Therapeutic focus 176

Research and development 177

Glossary 178

Index 179

List of Figures

Figure 2.1: Latin American pharmaceutical market comparison by Y-o-Y growth and CAGR (2004-08) 32

Figure 2.2: Market position of the top 10 pharmaceutical companies in Latin America, 2008 33

Figure 2.3: Key market drivers and resistors of Latin American 35

Figure 2.4: Share of top 10 pharmaceutical companies in Latin American market, 2008 36

Figure 2.5: Comparative analysis of top 10 companies 38

Figure 3.6: Sanofi-Aventis' revenue breakdown by geography in Latin America, 2007-08 48

Figure 3.7: Sanofi-Aventis' therapeutic focus in Latin America, 2007-08 50

Figure 3.8: Sanofi-Aventis' SWOT analysis 53

Figure 4.9: Novartis' revenue breakdown by geography in Latin America, 2007-08 58

Figure 4.10: Novartis' therapeutic focus in Latin America, 2007-08 60

Figure 4.11: Novartis' SWOT analysis 63

Figure 5.12: Bayer's revenue breakdown by geography in Latin America, 2007-08 68

Figure 5.13: Bayer's therapeutic focus in Latin America, 2007-08 70

Figure 5.14: Bayer's SWOT analysis 73

Figure 6.15: Pfizer's revenue breakdown by geography in Latin America, 2007-08 78

Figure 6.16: Pfizer's therapeutic focus in Latin America, 2007-08 80

Figure 6.17: Pfizer's SWOT analysis 83

Figure 7.18: Schering Plough's revenue breakdown by geography in Latin America, 2007-08 88

Figure 7.19: Schering Plough's therapeutic focus in Latin America, 2007-08 90

Figure 7.20: Schering Plough's SWOT analysis 93

Figure 8.21: EMS's revenue breakdown by geography in Latin America, 2007-08 97

Figure 8.22: EMS's therapeutic focus in Latin America, 2007-08 99

Figure 8.23: EMS's SWOT analysis, 2007-08 100

Figure 9.24: GSK's revenue breakdown by geography in Latin America, 2007-08 104

Figure 9.25: GSK's therapeutic focus in Latin America, 2007-08 106

Figure 9.26: GSK's SWOT analysis 111

Figure 10.27: Boehringer Ingelheim's geographic focus in Latin America, 2007-08 116

Figure 10.28: Boehringer Ingelheim's therapeutic focus in Latin America, 2007-08 118

Figure 10.29: Boehringer Ingelheim's SWOT analysis 120

Figure 11.30: Roche's revenue breakdown by geography in Latin America, 2007-08 124

Figure 11.31: Roche's therapeutic focus in Latin America, 2007-08 126

Figure 11.32: Roche's SWOT analysis 128

Figure 12.33: J&J's revenue breakdown by geography in Latin America, 2007-08 131

Figure 12.34: J&J's therapeutic focus in Latin America, 2007-08 133

Figure 12.35: J&J's SWOT analysis 135

Figure 13.36: AstraZeneca's revenue breakdown by geography in Latin America, 2007-08 139

Figure 13.37: AstraZeneca's therapeutic focus in Latin America, 2007-08 141

Figure 13.38: Ache Lab's revenue breakdown by geography in Latin America, 2007-08 143

Figure 13.39: Ache Labs' therapeutic focus in Latin America, 2007-08 145

Figure 13.40: Medley's revenue breakdown by geography in Latin America, 2007-08 147

Figure 13.41: Medley's therapeutic focus in Latin America, 2007-08 149

Figure 13.42: Merck & Co.'s revenue breakdown by geography in Latin America, 2007-08 151

Figure 13.43: Merck & Co.'s therapeutic focus in Latin America, 2007-08 153

Figure 13.44: Merck KGaA's revenue breakdown by geography in Latin America, 2007-08 155

Figure 13.45: Merck KGaA's therapeutic focus in Latin America, 2007-08 157

Figure 13.46: Nycomed Pharma's revenue breakdown by geography in Latin America, 2007-08 159

Figure 13.47: Nycomed Pharma's therapeutic focus in Latin America, 2007-08 161

Figure 13.48: Eli Lilly's revenue breakdown by geography in Latin America, 2007-08 163

Figure 13.49: Eli Lilly's therapeutic focus in Latin America, 2007-08 165

Figure 13.50: Wyeth's revenue breakdown by geography in Latin America, 2007-08 167

Figure 13.51: Wyeth's therapeutic focus in Latin America, 2007-08 169

Figure 13.52: Eurofarma's revenue breakdown by geography in Latin America, 2007-08 171

Figure 13.53: Eurofarma's therapeutic focus in Latin America, 2007-08 173

Figure 13.54: Teva's revenue breakdown by geography in Latin America, 2007-08 175

Figure 13.55: Teva's therapeutic focus in Latin America, 2007-08 177

List of Tables

Table 2.1: Latin American pharmaceutical market size by region ($m), 2008 32

Table 2.2: Demographic profile of Latin American countries, 2008 34

Table 2.3: Top 10 pharmaceutical companies in Latin America ($m), 2008 37

Table 3.4: Sanofi-Aventis snapshot 47

Table 3.5: Sanofi-Aventis' top 10 marketed product sales ($m), 2007-08 49

Table 3.6: Sanofi-Aventis' late-stage R&D pipeline, 2009 51

Table 4.7: Novartis snapshot 56

Table 4.8: Novartis' top 10 marketed product sales ($m), 2007-08 59

Table 4.9: Novartis' late-stage R&D pipeline, 2007–08 61

Table 5.10: Bayer snapshot 67

Table 5.11: Bayer's top 10 marketed product sales ($m), 2007-08 69

Table 5.12: Bayer's late-stage R&D pipeline, 2009 71

Table 6.13: Pfizer snapshot 77

Table 6.14: Pfizer's top 10 marketed product sales ($m), 2007-08 79

Table 6.15: Pfizer's late-stage R&D pipeline, 2009 81

Table 7.16: Schering Plough snapshot 87

Table 7.17: Schering Plough's top 10 marketed product sales ($m), 2007-08 89

Table 7.18: Schering Plough's late-stage R&D pipeline, 2009 91

Table 8.19: EMS snapshot 96

Table 8.20: EMS's top 10 marketed product sales ($m), 2007-08 98

Table 9.21: GSK snapshot 102

Table 9.22: GSK's top 10 marketed product sales ($m), 2007-08 105

Table 9.23: GSK's late-stage R&D pipeline, 2009 107

Table 10.24: Boehringer Ingelheim snapshot 114

Table 10.25: Boehringer Ingelheim's top 10 marketed product sales ($m), 2007-08 117

Table 10.26: Boehringer Ingelheim's late-stage R&D pipeline, 2009 119

Table 11.27: Roche snapshot 123

Table 11.28: Roche's top 10 marketed product sales ($m), 2007-08 125

Table 11.29: Roche's late-stage R&D pipeline, 2009 127

Table 12.30: J&J snapshot 130

Table 12.31: J&J's top 10 marketed product sales ($m), 2007-08 132

Table 12.32: J&J's late-stage R&D pipeline, 2009 134

Table 13.33: AstraZeneca snapshot 138

Table 13.34: AstraZeneca's top 10 marketed product sales ($m), 2007-08 140

Table 13.35: AstraZeneca's late-stage R&D pipeline, 2009 142

Table 13.36: Ache Labs snapshot 142

Table 13.37: Ache Labs' top 10 marketed product sales ($m), 2007-08 144

Table 13.38: Medley snapshot 146

Table 13.39: Medley's top 10 marketed product sales ($m), 2007-08 148

Table 13.40: Merck & Co.'s snapshot 150

Table 13.41: Merck & Co.'s top 10 marketed product sales ($m), 2007-08 152

Table 13.42: Merck & Co.'s late-stage R&D pipeline, 2009 154

Table 13.43: Merck KGaA snapshot 154

Table 13.44: Merck KGaA's top 10 marketed product sales ($m), 2007-08 156

Table 13.45: Merck KGaA's late-stage R&D pipeline, 2009 158

Table 13.46: Nycomed Pharma snapshot 158

Table 13.47: Nycomed Pharma's top 10 marketed product sales ($m), 2007-08 160

Table 13.48: Nycomed Pharma's late-stage R&D pipeline, 2009 162

Table 13.49: Eli Lilly snapshot 162

Table 13.50: Eli Lilly's top 10 marketed product sales ($m), 2007-08 164

Table 13.51: Eli Lilly's late-stage R&D pipeline, 2009 166

Table 13.52: Wyeth snapshot 166

Table 13.53: Wyeth's top 10 marketed product sales ($m), 2007-08 168

Table 13.54: Eurofarma snapshot 170

Table 13.55: Eurofarma's top 10 marketed product sales ($m), 2007-08 172

Table 13.56: Teva snapshot 174

Table 13.57: Teva's top 10 marketed product sales ($m), 2007-08 176

Table 13.58: Teva's late-stage R&D pipeline, 2009 177

Companies mentioned

Ache Labs , AstraZeneca , Bayer , Boehringer Ingelheim , Eli Lilly , EMS , Eurofarma , GlaxoSmithKline , Johnson & Johnson , Medley , Merck & Co. , Merck KGaA , Novartis , Nycomed Pharma , Pfizer , Roche , Schering Plough , Teva , Wyeth , Sanofi-Aventis ,

To order this report:

Pharmaceutical Industry: The Top 10 Pharmaceutical Companies in Latin America: Growth performance, strategies and SWOT analysis

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker